US2016069902A1PendingUtilityA1
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
Est. expirySep 20, 2021(expired)· nominal 20-yr term from priority
A61P 37/02A61P 35/02A61P 5/14A61P 35/00A61P 37/06A61P 27/02A61P 25/00Y10S436/809A61P 19/02G01N 33/6872Y10T436/107497A61P 13/10Y10S424/81G01N 33/6893G01N 2333/70596A61P 13/08C07K 16/2887G01N 2800/52G01N 33/564Y10T436/106664C07K 2317/76C07K 2317/24G01N 33/57557G01N 33/5759
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
Claims
exact text as granted — not AI-modified1 .- 73 . (canceled)
74 . A method for determining a dosage of a therapeutic anti-CD20 antibody, the method comprising testing a sample from a human to measure the level of soluble CD20, wherein a high level of said soluble CD20 indicates that said human is to be treated with a high dosage of said therapeutic anti-CD20 antibody.
75 . The method of claim 74 , wherein said sample is selected from the group consisting of plasma, serum, and cell lysate.
76 . The method of claim 74 , wherein said therapeutic anti-CD20 antibody is Rituximab.
77 . The method of claim 74 , wherein said human is being treated for a B cell hyperproliferative disease.
78 . The method of claim 77 , wherein said B-cell hyperproliferative disease is chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, juvenile myelomonocyte leukemia, multiple myeloma, hairy cell leukemia, prolymphocytic leukemia, or lymphoma
79 . The method of claim 77 , wherein said B-cell hyperproliferative disease is chronic lymphocytic leukemia.
80 . The method of claim 74 , further comprising administering said therapeutic anti-CD20 antibody to said human.
81 . The method of claim76, further comprising administering said Rituximab to said human.Join the waitlist — get patent alerts
Track US2016069902A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.